肿瘤治疗中小分子激酶抑制剂的研究进展

Advances in small molecule kinase inhibitors for cancer treatment

激酶在肿瘤细胞的生长、增殖和凋亡过程中起着重要作用,因此,研发相关的激酶抑制剂调控相应的信号转导通路已是现今抗肿瘤药物开发的趋势。至今,已有29个肿瘤小分子激酶抑制剂经美国食品药品监督管理局批准进入临床。现就肿瘤小分子激酶抑制剂的分类和作用机理进行分析和总结,并系统阐述肿瘤小分子激酶抑制剂的研究进展和发展趋势。

Kinases, which play an important role in cancer cell growth, proliferation and apoptosis, are currently one of the intensively pursued targets in development of anti-tumor drugs. To date, the United States Food and Drug Administration （FDA） has approved 29 small molecule kinase inhibitors for cancer treatment. Here, we summarized the classification and mechanism of these small molecule kinase inhibitors, and described the research progress and development trend of small molecule kinase inhibitors.